Phase III Study of VCAP-AMP-VECP vs. Biweekly CHOP in Aggressive Adult T-cell Leukemia-lymphoma (ATLL): Japan Clinical Oncology Group Study, JCOG9801.

To test the superiority of VCAP-AMP-VECP regimen over biweekly-CHOP in aggressive ATLL in terms of survival benefit.

开始日期1998-08-01

申办/合作机构-

100 项与雷莫司汀相关的临床结果

登录后查看更多信息

100 项与雷莫司汀相关的转化医学

登录后查看更多信息

100 项与雷莫司汀相关的专利（医药）

登录后查看更多信息

347

项与雷莫司汀相关的文献（医药）

2025-04-01·Brain Tumor Pathology

Discordant lymphoma characterized by the coexistence of diffuse large B-cell lymphoma in the brain and mantle cell lymphoma in the colon, rectum, and bone marrow

Article

作者: Uchida, Naoyuki ; Ito, Shinji ; Uruga, Hironori ; Kaji, Daisuke ; Yamaguchi, Kyosuke ; Kageyama, Kosei ; Takagi, Shinsuke ; Nishida, Aya ; Yamamoto, Go ; Taya, Yuki ; Takazawa, Yutaka ; Wake, Atsushi ; Watanabe, Otoya ; Yamamoto, Hisashi ; Ishiwata, Kazuya ; Asano-Mori, Yuki ; Taniguchi, Shuichi

We describe a rare case of discordant lymphoma characterized by the coexistence of diffuse large B-cell lymphoma (DLBCL) in the brain and mantle cell lymphoma (MCL) in the colon, rectum, and bone marrow. A 63-year-old male patient with consciousness impairment and gait disturbance was admitted to our institution. Head computed tomography scan and contrast-enhanced magnetic resonance imaging showed a mass in the right temporal lobe and rectal wall thickening. Brain biopsy revealed DLBCL, and bone marrow and rectum biopsy showed MCL. According to a polymerase chain reaction analysis of immunoglobulin heavy-chain gene rearrangements using brain and bone marrow specimens, the two lesions were clonally unrelated lymphomas. After five cycles of R-MPV (rituximab, methotrexate, procarbazine, vincristine) therapy and three cycles of R-ESHAP (rituximab, etoposide, cytarabine, cisplatin, methylprednisolone) therapy, the patient received autologous hematopoietic stem cell transplantation using R-MEAM (rituximab, ranimustine, etoposide, cytarabine, melphalan) regimen after bridging therapy with ibrutinib. In addition, he received whole-brain irradiation at a dose of 40 Gy in 20 fractions as consolidation therapy. He did not relapse within 3 years of transplantation. To the best of our knowledge, this is the first case report of DLBCL and MCL coexistence.

2024-01-01·Journal of Clinical and Experimental Hematopathology

Evaluation of the effects of MCVAC conditioning regimen followed by autologous hematopoietic stem cell transplantation in patients with relapsed and refractory Hodgkin lymphoma: A single-institution retrospective study

Article

作者: Momose, Shuji ; Tabayashi, Takayuki ; Higashi, Morihiro ; Anan, Tomoe ; Takahashi, Yasuyuki ; Kizaki, Masahiro ; Naganuma, Ken

High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HDC/ASCT) has been useful in relapsed or refractory classic Hodgkin lymphoma (RRcHL). Furthermore, a ranimustine, cytarabine, etoposide, and cyclophosphamide (MCVAC) conditioning regimen has been effective in diffuse large B-cell lymphoma. However, limited data are available regarding this conditioning regimen for cHL. In this study, we investigated the efficacy and toxicity of MCVAC for RRcHL. We retrospectively analyzed 10 patients with RRcHL who underwent ASCT preceded by the MCVAC conditioning regimen between January 2009 and December 2021 at our institution. A total of 10 patients (median [range] age, 36 [23-64] years), including 5 (50%) men and 5 (50%) women, were treated with the MCVAC regimen followed by ASCT. The median follow-up duration of the 10 patients was 25.0 months. The 36-month PFS and OS rates were 43.8% (95% CI, 11.9%-72.6%) and 64.0% (95% CI, 22.6%-87.5%), respectively. Two patients died because of treatment-related factors, and one patient died because of disease progression. Based on our findings, recognizing the risk factors for adverse events (AEs) associated with this treatment, MCVAC may be a valid treatment option for the management of RRcHL.

2024-01-01·[Rinsho ketsueki] The Japanese journal of clinical hematology

[Long-term remission of non-Hodgkin lymphoma secondary to the treatment for essential thrombocythemia].

Article

作者: Waki, Masato ; Kubota, Yoshitsugu

A 45-year-old woman was diagnosed with essential thrombocythemia (ET) in August 1987 and received treatment with alkylating agents (total administration dose, busulfan 378 mg, MCNU 700 mg) because of a history of myocardial infarction. In June 2000, anemia gradually progressed. A few blast cells were detected in the peripheral blood at that time. Since bone marrow biopsy revealed myelofibrosis, she received anabolic hormone therapy. She was admitted to our hospital for an evaluation of abdominal distension in February 2003. Swelling of a large paraaortic lymph node of 6 cm in diameter was detected by CT scan. Lymph node biopsy revealed diffuse large B-cell lymphoma. Lymphoma cells were positive for CD10, CD19, CD20 and kappa-chain. The clinical stage was I. Complete remission has been achieved for 57 months after treatment with combination chemotherapy combined with rituximab followed by local radiation therapy. Non-Hodgkin lymphoma secondary to ET is a rare event. Such cases should therefore be accumulated to evaluate the mechanism of onset and clinical characteristics of lymphoma secondary to ET.

100 项与雷莫司汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01760	雷莫司汀	L01AD07	DB13832

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
急性髓性白血病	日本	Nipro ES Pharma KK	1987-01-12
食管癌	日本	Nipro ES Pharma KK	1987-01-12
肺癌	日本	Nipro ES Pharma KK	1987-01-12
淋巴瘤	日本	Nipro ES Pharma KK	1987-01-12